glp-1 market size 2024 Agonists Weight Loss Drugs Report, 2025-2030 GLP-1 Receptor Agonist Market Size,

A surgeons ability to offer both surgical and non-surgical options is an important differentiator in 2026

This means: They underwent extensive clinical trials Dosing, purity, and manufacturing are strictly regulates Safety and efficacy were evaluated in thousands of patients The formulation is standardized and consistent FDA approval ensures that what you are receiving has been rigorously tested for both safety and predictable results

This is relevant as the drug predominantly used off-label for IIH, acetazolamide, can be poorly tolerated

Obesity has impacts on cardiovascular disease outcomes through increased risk of coronary artery disease, heart failure (more prominent with preserved ejection fraction), cardiac arrhythmias (most significantly atrial fibrillation), sudden death, and venous thromboembolism [7]